Andreas Bockisch
Overview
Explore the profile of Andreas Bockisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
5910
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moraitis A, Prochnow A, Poeppel T, Schmitz J, Laschinsky C, Herrmann K, et al.
J Nucl Med
. 2025 Mar;
PMID: 40081949
[I]Metaiodobenzylguanidine (MIBG) therapy in patients with neural crest tumors has demonstrated sustained control of catecholamine-associated hypertension and corresponding partial response. Details on how neural crest tumors respond to an absorbed...
2.
Bellendorf A, Mader N, Mueller S, Ezziddin S, Bockisch A, Grafe H, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256934
Transarterial chemoembolization (TACE) is currently the standard of care in patients with unresectable hepatocellular carcinoma (HCC), and selective internal radionuclide therapy (SIRT) with Y microspheres is mainly used as an...
3.
Moraitis A, Jentzen W, Reiter G, Schmitz J, Poppel T, Weber M, et al.
EJNMMI Phys
. 2024 Jan;
11(1):3.
PMID: 38167953
Aim: Positron emission tomography (PET) using I-mIBG has been established for imaging and pretherapeutic dosimetry. Here, we report the first systematic analysis of the biodistribution and radiation dosimetry of I-mIBG...
4.
Maric I, Weber M, Prochnow A, Schmitz J, Unger N, Schaarschmidt B, et al.
J Nucl Med
. 2023 Feb;
64(6):885-891.
PMID: 36732054
We aim to evaluate the efficacy and safety of I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-activity I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. Fourteen patients with advanced pheochromocytoma or neuroblastoma, age 9-69 y,...
5.
Weber M, Kersting D, Riemann B, Brandenburg T, Fuhrer-Sakel D, Grunwald F, et al.
Clin Cancer Res
. 2022 May;
28(19):4194-4202.
PMID: 35594174
Purpose: Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAFV600E-mutant (BRAF-MUT) RR-TC. Here we assess safety...
6.
Broecker-Preuss M, Becher-Boveleth N, Muller S, Huttmann A, Hanoun C, Grafe H, et al.
J Cancer Res Clin Oncol
. 2021 Oct;
148(10):2611-2621.
PMID: 34708297
Background: [F]Fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging procedure in diffuse large B-cell lymphoma (DLBCL). Disease presentation, FDG-PET/CT performance, and outcome may be influenced by germline...
7.
Farahati J, Kazek S, Maric I, Soestwoehner T, Kalle P, Fragoso Costa P, et al.
Appl Radiat Isot
. 2019 Sep;
154:108853.
PMID: 31493660
Currently, there is no imaging procedure for radionuclide therapy utilizing Erbium-169 (Er-169). We have recently published the first post-radiosynovectomy imaging of Er-169 citrate in a case report (Farahati et al.,...
8.
Weber M, Binse I, Nagarajah J, Bockisch A, Herrmann K, Jentzen W
Q J Nucl Med Mol Imaging
. 2019 Jul;
63(3):235-252.
PMID: 31298014
Radioiodine therapy of thyroid cancer was the first successful radionuclide therapy in the treatments of cancer, although its clinical use is empirical and not based on precise dosimetry. 124I is...
9.
Farahati J, Mader U, Gilman E, Gorges R, Maric I, Binse I, et al.
Nuklearmedizin
. 2019 Mar;
58(2):86-92.
PMID: 30917397
Aim: to evaluate the time trend of epidemiology of follicular cell derived thyroid cancer (TC) based on data from a well documented cancer registry. Methods: Population based data on TC...
10.
Domouchtsidou A, Barsegian V, Mueller S, Lobachevsky P, Best J, Horn P, et al.
Cancer Immunol Immunother
. 2019 Mar;
68(6):907-915.
PMID: 30877323
In patients with non-resectable hepatic malignancies selective internal radiotherapy (SIRT) with yttrium-90 is an effective therapy. However, previous data indicate that SIRT leads to impaired immune function. The aim of...